Skip to main content
. 2021 Jan 14;57(1):10–16. doi: 10.1007/s11626-020-00535-5

Figure 3.

Figure 3.

Effects of SB203580 and U0126 on the DEX-induced upregulation of CD163 expression. IPKM were treated with (AD) or without (EH) 80 ng/ml DEX for 1 d in the presence or absence of 10 μM SB203580 (C, G) or 10 μM U0126 (D, H). DMSO (0.1%) was used as a vehicle control (B, F) because SB203580 and U0126 were dissolved in DMSO. Then, the cells were fixed and immunostained with a specific antibody against CD163 (brown). All nuclei were counterstained with hematoxylin (blue). DEX enhanced the expression of CD163 compared with that seen in the untreated cells (A, E), even in the presence of DMSO (B, F). SB203580 and U0126 had no effect on the basal CD163 expression level (C, D). However, SB203580 blocked the DEX-induced enhancement of CD163 expression (G), while U0126 did not exert any such inhibitory effect (H).